Related Experiment Video

Updated: Jun 17, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia

Chikashi Yoshida1, Tomoiku Takaku2

  • 1Department of Hematology, NHO Mito Medical Center, Ibaraki, Japan.

Med (New York, N.Y.)
|August 10, 2024
PubMed

Insights

Asciminib, a novel BCR::ABL1 inhibitor, demonstrated superior efficacy and safety over standard tyrosine kinase inhibitors (TKIs) in newly diagnosed chronic myeloid leukemia patients. This finding offers a promising new treatment option for chronic myeloid leukemia (CML).

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Standard treatment for chronic myeloid leukemia (CML) involves tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1.
  • Asciminib is a BCR::ABL1 inhibitor with a distinct mechanism, targeting the ABL myristoyl pocket.

Purpose of the Study:

  • To evaluate the efficacy and safety of asciminib compared to standard TKIs in patients with newly diagnosed chronic-phase CML.

Main Methods:

  • Phase 3 randomized controlled trial (ASC4FIRST trial).
  • Comparison of asciminib versus standard TKIs in newly diagnosed chronic-phase CML patients.

Main Results:

  • Asciminib showed superior efficacy compared to standard TKIs.
  • Asciminib demonstrated a favorable safety profile in this patient population.

Conclusions:

  • Asciminib represents a superior and safer treatment option for newly diagnosed chronic myeloid leukemia.
  • Targeting the ABL myristoyl pocket with asciminib offers a new therapeutic strategy for CML.

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

45

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
151